A Study of Intermittent Doses of CERC-301 in MDD
Public ClinicalTrials.gov record NCT02459236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
There is a significant unmet medical need for rapidly acting treatment of subjects with severe major depressive disorder (MDD) who have not adequately responded to antidepressant therapy. Alternative therapies require weeks to achieve full efficacy, may have significant side effects, and still fail in a high percentage of subjects. Rapid reduction of severe depression by pharmacological therapy is important to reduce the need for hospitalization and risk of self-harm and mortality. CERC-301, a highly selective, orally bioavailable, N-methyl-D-aspartate (NMDA) receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist, would be a therapeutic breakthrough if it provides rapid onset of antidepressant effects and an effect size similar to that seen with experimental intravenous NMDA modulators.
Study identification
- NCT ID
- NCT02459236
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2015
- Primary completion
- Aug 31, 2016
- Completion
- Nov 30, 2016
- Last update posted
- Sep 27, 2017
2015 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pharmacology Research Institute (PRI) | Newport Beach | California | 92660 | — |
| Institute for Advanced Medical Research | Alpharetta | Georgia | 30005 | — |
| Chicago Research Center, Inc. | Chicago | Illinois | 60634 | — |
| Alexian Brothers Center for Psychiatric Research | Hoffman Estates | Illinois | 60169 | — |
| Psychiatric Care and Research Center | O'Fallon | Missouri | 63368 | — |
| Bioscience Research LLC | Mount Kisco | New York | 10549 | — |
| The Medical Research Network, LLC | New York | New York | 10128 | — |
| Fingerlakes Clinical Research | Rochester | New York | 14618 | — |
| Richmond Behavioral Associates | Staten Island | New York | 10312 | — |
| Summit Research Network (Oregon) Inc. | Portland | Oregon | 97201 | — |
| Lehigh Center for Clinical Research | Allentown | Pennsylvania | 18104 | — |
| Research Strategies of Memphis, LLC | Memphis | Tennessee | 38119 | — |
| Northwest Clinical Research Center | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02459236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2017 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02459236 live on ClinicalTrials.gov.